80mg Osimertinib New Drug For Non Small Cell Lung Cancer 30 Tablets

[Drug Name

Generic Name:MesylateOsimertinib Tablets

Product Name: Terrisa®/TAGRISSO®

English name: Ositinib mesylate tablets

hanyu Pinyin: Jiahuangsuan Aoxitini Pian

indications

This product is suitable for:

For the treatment of patients with stage IB-IIIA epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation in non-small cell lung cancer (NSCLC). Patients must have undergone prior surgical resection and receive or not receive adjuvant chemotherapy at the physician's discretion.

First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation.

To treat adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or after prior treatment with an EGFR tyrosine kinase inhibitor (TKI) and have been tested for the EGFR T790M mutation.

Dosage

This product should be prescribed by a physician experienced in antitumor therapy. The presence of an EGFR exon 19 deletion mutation or exon 21 L858R substitution mutation, or the presence of an EGFR-T790M mutation should be confirmed by an SDA-approved EGFR genetic test prior to treatment with this product.

dosages

• The recommended dose of this product is 80 mg daily.

Treatment time

• Patients with postoperative lung cancer should continue treatment until disease recurrence or intolerable toxicity or for a maximum of 3 years. Patients with locally advanced or metastatic lung cancer should continue treatment until disease progression or intolerable toxicity.

drug leak

• If you miss a dose of this product, you should take it again unless the next dose is within 12 hours.

• This product should be taken at the same time each day, with a meal or on an empty stomach.

Dosage adjustment

• Depending on the safety and tolerability of individual patients, dosing may be suspended or reduced. If dose reduction is required, the dose should be reduced to 40 mg once daily.

special group

• No dosage adjustments are necessary based on patient age, weight, gender, race, and smoking status.

Method of administration

• This product is for oral administration. This product should be taken whole with water and should not be crushed, broken or chewed.

• If the patient is unable to swallow the medication, dissolve the tablets in 50mL of carbonate-free water. The tablets should be plunged into the water, not crushed, and stirred directly until dispersed and swallowed quickly. Then add ½ cup of water, making sure there is no residue in the cup, and drink it quickly. No other liquids should be added.

• When gastric tube feeding is required, it can be handled in the same manner as described above, except that 15mL of water is used for initial dissolution of the drug and 15mL of water is used for subsequent washing of the residue. This 30mL of liquid should be fed according to the nasogastric tube manufacturer's instructions and washed with an appropriate amount of water. These solutions and residues should be removed within 30 minutes of adding the tablets to the water.

adverse reaction

• The most common adverse drug reactions were diarrhea (47%), rash (45%), onychomycosis (33%), dry skin (32%), and oral mucositis (24%).

pre-harvest

•  

  Keep it below 30℃.
   

  Name	Osimertinib
  Dosage	80mg
  Quantity	30's
  Indications	EGFR gene mutation non-small cell lung cancer
  Weight	<1kg
  Outer packaging	box
  Storage temperature	normal temperature
  Ingredients	Comply with regulations
  Auxiliary agents	comply with regulations
  Enteric curve	meets regulations